Navigation Links
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
Date:5/14/2013

TAIPEI, Taiwan, May 14, 2013 /PRNewswire/ -- TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration (U.S. FDA). Guanfacine Hydrochloride Extended-Release Tablet is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

"We are pleased to receive the tentative approval from U.S. FDA for our Guanfacine Hydrochloride product," said Dr. Calvin C. Chen , President of TWi Pharmaceuticals. "TWi had already reached a settlement agreement with the branded product manufacturer and intends to begin shipping its Guanfacine Hydrochloride product upon receiving the final approval from U.S. FDA."

According to IMS Health, a market research firm, the total annual sales of the branded product, Intuniv®, marketed by Shire US Inc., in U.S. were approximately $448 million in 2012.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:

Michael L. Huang
Head of Investor Relations
Tel: +886-2-2657-3350
Email: michael.huang@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
2. Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
3. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
4. Arbor Pharmaceuticals Announces FDA Approval of First NDA
5. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
6. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
7. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
8. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
11. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Nearly 30 million people in the ... diabetes. 1 However, nearly 40% of diabetes patients ... and significant glucose variability. 2 These patients are at ... If left untreated, hyperglycemia can lead to cardiovascular disease, ... 3 As part of Diabetes Awareness ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Delaware , December 6, 2016 Breast Pump ... per a new research report by Global Market Insights, Inc. ... ... logo , ... Increasing global population, growing women employment rates and rising consumer awareness regarding ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma ... by cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation ... New Mexico has more people with cavernous angioma than anywhere in the world. ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... their brain networks that can be seen on a type of MRI, according ... is a progressive disorder of the central nervous system characterized by tremors or ...
(Date:12/6/2016)... ... , ... An inventor, from Talladega, Ala., thought there needed to be a ... SLING-VEST. , The SLING-VEST provides an effective way to support and align the arm ... a result, it helps to reduce discomfort and shifting. The invention features an effective ...
(Date:12/6/2016)... ... 2016 , ... In anticipation for the New Year, Dr. Mayoor Patel has ... courses in 2017, dentists of all levels can continue to advance the services offered ... attend a variety of continuing education courses each month on topics ranging from sleep ...
Breaking Medicine News(10 mins):